Pompano Beach, FL, March 13, 2020 — BioStem Life Sciences, a wholly owned subsidiary of BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”) a leading life sciences company specializing in perinatal tissue-based allografts for use in regenerative therapies, today announced the buildout of a brand new R&D lab. Situated in the Company’s 6,100 sq. Ft., state-of-the-art, FDA registered, cGMP facility, this new lab will support the research and development pipeline for the Company’s growing Contract Development and Manufacturing (CDMO) business. [Read more…]
The International Perinatal Stem Cell Society is a non-profit organization founded on the principle that stem cells from perinatal tissues contain enormous, untapped potential to treat many diseases and disorders worldwide.
For many years, the Perinatal Stem Cell Society has been hosting an annual conference featuring the world’s leading perinatal stem cell researchers, specializing in Amnion, Amniotic Fluid, Cord Blood for Regenerative Medicine, Cord Tissue, and the Placenta. Its scientific programs cover all aspects of the perinatal stem cell field, with opportunities to learn from leading clinicians utilizing cellular therapies within their practices.
Below, Kyle Cetrulo, President of the International Perinatal Stem Cell Society, explains the future of perinatal stem cell science and the role that the Society’s 2020 Scientific Conferences will play in advancing this mission. [Read more…]
Signature Matrix and Signature Cord are the culmination of decades of research and clinical use of perinatal tissue by applied stem cell research expert and Amazon best-selling author, Neil Riordan, PA, PhD, and his experienced research and development team.
Signature Cord is a flowable umbilical cord tissue allograft that originates from the same tissue used to manufacture the purified, expanded mesenchymal stem cell product used by Stem Cell Institute in Panama to treat a variety of chronic conditions. This product is a natural source of growth factors and hyaluronic acid, and is naturally immune evasive. Most importantly, our proprietary Signature Process of manufacturing does not alter the innate regenerative properties of the umbilical cord tissue and maintains the source material integrity required for tissue repair. [Read more…]
After a rapid growth period through the mid-2000s, the global cord blood banking market reached saturation and stabilized through approximately 2012. Since that time, the market has been aggressively consolidating.
In this article:
- Cord Blood Industry Consolidation in the U.S.
- Cord Blood Industry Consolidation in Europe
- Cord Blood Industry Consolidation in Asia
- Cord Blood Industry Consolidation in Latin America
- Cord Blood Industry Consolidation in India
- Trend of Umbilical Cord Blood Industry Consolidation
Cord blood banking initially emerged as a commercial service in the late 1980’s and early 1990’s, because of potential applications related to Transplant Medicine. While an effective therapeutic approach, this unfortunately produced low utilization rates for stored cord blood units.
As a result, Regenerative Medicine (RM) applications of cord blood emerged over time, expanding approved used for cord blood to approximately 80 total. Exciting regenerative medicine applications for umbilical cord blood include its potential to treat neurological conditions, such as cerebral palsy (CP) and autism. These applications are being researched by one of the luminaries in the field, Dr. Joanne Kurtzberg of the Duke Center for Autism and Brain Development and the Carolinas Cord Blood Bank.
As the cord blood market has expanded to include a wide range of perinatal tissues, including umbilical cord tissue, placental blood and tissue, and amniotic fluid and tissue, the new frontier has become Longevity applications. Perinatal is a term describing the period right before and after birth. [Read more…]